Association Briefs

The Federation of American Societies for Experimental Biology is considering measures to boost its membership and promote biomedical research, as well as redefine its financial structure. FASEB president William L. Dewey, associate provost for research and graduate affairs at Virginia Commonwealth University, says that the Bethesda, Md.-based organization wants to become more attractive to both its current seven societies and potential new members by making FASEB membership less expensive and h

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

The Federation of American Societies for Experimental Biology is considering measures to boost its membership and promote biomedical research, as well as redefine its financial structure. FASEB president William L. Dewey, associate provost for research and graduate affairs at Virginia Commonwealth University, says that the Bethesda, Md.-based organization wants to become more attractive to both its current seven societies and potential new members by making FASEB membership less expensive and having the group's meeting structure more flexible. He says he wants the federation's primary goal to focus on public affairs, which would be timely, since FASEB recently joined Research!America, a coalition promoting public support for biomedical research. Another change could involve the federation's fiscal dues policy, which currently charges each society $60 per individual member. A new policy being discussed would require societies to pay only for services that it wishes to use (like publications). FASEB also is seeking a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies